Hangzhou Tigermed Consulting Co., Ltd

300347

CNE100001KV8

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 12/05/2024 BST			5-day change	1st Jan Change
57.68 ^CNY	-3.37%		-6.59%	+4.93%

04-25	Hangzhou Tigermed Consulting’s Profit Down 59% in Q1	MT
04-25	Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024	CI

Hangzhou Tigermed Consulting Co., Ltd Approves Appointment of Ms. Yang Chengcheng as the Chief Financial Officer

May 23, 2023 at 03:16 pm

Hangzhou Tigermed Consulting Co. Ltd. considered and approved appointment of Ms. Yang Chengcheng as the chief financial officer of the Company.

Latest news about Hangzhou Tigermed Consulting Co., Ltd

Hangzhou Tigermed Consulting’s Profit Down 59% in Q1	04-25	MT
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024	04-25	CI
Tigermed Consulting's Profit, Revenue Climb in 2023	03-29	MT
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes	03-21	CI
China Healthcare Stocks Rally on Hopes for Government Support	03-14	DJ
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	03-14	RE
Nomura Downgrades Hangzhou Tigermed Consulting to Neutral From Buy, Adjusts Price Target to 49.61 Yuan From 75.72 Yuan	03-05	MT
Nomura Downgrades Tigermed to Neutral From Buy, Adjusts Price Target to HK$32.69 From HK$57.77	03-05	MT
Hangzhou Tigermed Consulting Plans Up to 1 Billion Yuan Share Repurchase; Shares Jump 4%	02-07	MT
Hangzhou Tigermed Consulting Co., Ltd announces an Equity Buyback for CNY 1,000 million worth of its shares.	02-06	CI
Hangzhou Tigermed Consulting Co., Ltd authorizes a Buyback Plan.	02-05	CI
Nomura Adjusts Hangzhou Tigermed Consulting' Price Target to 75.72 Yuan from 83.50 Yuan, Keeps at Buy	30/10/23	MT
Nomura Adjusts Hangzhou Tigermed Consulting' Price Target to HK$57.77 from HK$64.46, Keeps at Buy	30/10/23	MT
Hangzhou Tigermed Consulting's Profit Up 19% in Q3	27/10/23	MT
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
Tigermed Consulting's Profit Jumps 16.5% in H1	28/08/23	MT
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23	CI
Tigermed Officially Opens International Headquarters in Hong Kong	17/08/23	CI
Bioclub announced that it has received funding from Hangzhou Tigermed Consulting Co., Ltd	06/08/23	CI
Nomura Adjusts Tigermed to Buy From Neutral, Adjusts Price Target to 83.50 Yuan From 91.67 Yuan	24/07/23	MT
Nomura Upgrades Tigermed to Buy From Neutral, Adjusts Price Target to HK$64.46 From HK$79.47	24/07/23	MT
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $63.25 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd., Beijing Konruns Pharmaceutical Co.,Ltd., Hangzhou Tigermed Consulting Co., Ltd, Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd., Yingke Innovation Asset Management Co., Ltd.	19/06/23	CI
Hangzhou Tigermed Consulting Names Chairman, Other Officials	24/05/23	MT
Hangzhou Tigermed Consulting Co., Ltd Approves Appointment of Ms. Yang Chengcheng as the Chief Financial Officer	23/05/23	CI

Chart Hangzhou Tigermed Consulting Co., Ltd

Duration

Period

Chart Hangzhou Tigermed Consulting Co., Ltd

More charts

Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows: - provision of clinical trial services and related technological services (51.8%); - provision of clinical research consulting services (48.2%). China accounts for 46% of sales.

Sector

Biotechnology & Medical Research

Calendar

24/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Hangzhou Tigermed Consulting Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

57.68 CNY

Average target price

72.84 CNY

Spread / Average Target

+26.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HANGZHOU TIGERMED CONSULTING CO., LTD	+4.93%	6.44B
MODERNA, INC.	+26.37%	48.16B
IQVIA HOLDINGS INC.	-1.01%	41.73B
LONZA GROUP AG	+41.87%	41.03B
CELLTRION, INC.	-5.31%	28.77B
ICON PUBLIC LIMITED COMPANY	+9.34%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	18.96B
BIO-TECHNE CORPORATION	+6.23%	12.92B
MEDPACE HOLDINGS, INC.	+26.99%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	11.77B

Other Biotechnology & Medical Research